$ENTA (Enanta Pharmaceuticals, Inc.)

$ENTA {{ '2016-09-30T13:00:17+0000' | timeago}} • Announcement

$ENTA said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for $ABBV's investigational chronic hepatitis C virus (HCV) regimen. The BTD is granted based on phase 2 Magellan-1 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs).

$EVHC {{ '2017-09-19T12:30:35+0000' | timeago}} • Announcement

As part of $EVHC's organizational changes, Karey Witty, a veteran healthcare executive, has been appointed to the new role of EVP and COO, effective Oct 2, 2017. Kevin Eastridge, currently CAO, will succeed Claire Gulmi as CFO, effective same day.

$EVHC {{ '2017-09-19T12:24:50+0000' | timeago}} • Announcement

$EVHC announced the authorization of a program to repurchase up to $250MM of its common stock, which represents approx 4% of its current market capitalization.

$BSX {{ '2017-09-18T14:02:45+0000' | timeago}} • Announcement

$BSX announced results from a 3-year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study. The patients with severe asthma show sustained clinical improvement and the data confirmed long-term effectiveness of Bronchial Thermoplasty.

$ALXN {{ '2017-09-14T20:51:47+0000' | timeago}} • Announcement

Biopharmaceutical company $ALXN named Paul Friedman to its board of directors. Friedman had served as President and CEO of Incyte Corp. from 2001 to 2014. He succeeds Douglas Norby, who retired after serving on Alexion's board for 18 years. The company said Alvin Parven has decided not to stand for re-election as director.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$ENTA {{ '2017-09-13T14:09:33+0000' | timeago}} • Announcement

Pharmaceuticals company $ENTA has appointed Kristine Peterson to its BoD, raising the total number of directors to seven. Peterson had served as CEO of Valeritas Inc from 2009 to 2016. Earlier, she held marketing and commercial positions at Johnson & Johnson, most recently as Company Group Chair of the biotech division.

$ALXN {{ '2017-09-12T13:18:41+0000' | timeago}} • Announcement

$ALXN has charted out a re-alignment plan, with its refocused corporate strategy. The initiative is expected to deliver annual pre-tax savings of about $270MM (GAAP) and $250MM (non-GAAP) by 2019. The restructuring will reduce the company's workforce by 20%. The total pre-tax restructuring expenses are expected to be between $340MM and $440MM.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$BMY {{ '2017-09-07T13:34:21+0000' | timeago}} • Announcement

$BMY said a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary endpoint. This demonstrates superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients.

$BAX {{ '2017-08-31T13:27:20+0000' | timeago}} • Announcement

$BAX and MATTER announced a new collaboration to drive forward innovation focused on improving the value and quality of healthcare. This new partnership builds on $BAX's recently announced research collaborations with Mayo Clinic, Tel Aviv University and Tel Aviv Sourasky Medical Center.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$AGN {{ '2017-08-29T10:53:21+0000' | timeago}} • Announcement

$AGN and its subsidiaries reached a settlement regarding its litigation with Famy Care Ltd. relating to the company's patent covering Restasis (Cyclosporine Ophthalmic Emulsion). All Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review.

$ALXN {{ '2017-08-24T19:55:21+0000' | timeago}} • Announcement

$ALXN said John Orloff has been appointed Head of Research and Development. Anne-Marie Law has joined the company as Chief Human Resources Officer and Indrani Franchini has joined as Chief Compliance Officer. All appointments are effective June 5, 2017, and the officers will report to CEO, Ludwig Hantson.

$ALXN {{ '2017-08-21T14:02:22+0000' | timeago}} • Announcement

Pharma firm $ALXN obtained approval from the European Commission for extension of the indication for Soliris, a medication for ailments affecting the immune system, to include treatment of refractory generalized myasthenia gravis. The approval was granted based on clinical data from a phase-3 REGAIN study and long-term open-label extension study.

$ALXN {{ '2017-08-15T20:45:14+0000' | timeago}} • Announcement

$ALXN announced that the United States Patent and Trademark Office (USPTO) has issued three new patents for Soliris. These will expire in 2027. The company is pursuing corresponding patent applications in other regions and countries, including Europe and Japan.

Recent Transcripts

CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
TSRO (Tesaro, Inc.)
Tuesday, August 8 2017 - 8:15pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
ENTA (Enanta Pharmaceuticals, Inc.)
Monday, August 7 2017 - 8:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
SHPG (Shire plc)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, August 3 2017 - 12:00pm
CAH (Cardinal Health, Inc.)
Wednesday, August 2 2017 - 12:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm
BSX (Boston Scientific Corporation)
Thursday, July 27 2017 - 12:00pm
BAX (Baxter International Inc.)
Wednesday, July 26 2017 - 12:30pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
TSRO (Tesaro, Inc.)
Tuesday, May 9 2017 - 8:15pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
ENTA (Enanta Pharmaceuticals, Inc.)
Monday, May 8 2017 - 8:30pm

AlphaGraphics you may like